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Background: Osteoporosis is a metabolic skeletal disease with low bone mass and
bone microarchitectural disorganization. Thiazolidinediones (TZD) increase insulin
sensitivity through activation of peroxisome proliferator-activated receptor gamma
(PPARγ). One of the most important side effects of this drugs is its effects on bone,
especially in postmenopausal women. The purpose of this study was to evaluate the
effect of diabetes mellitus (DM), insulin, and TZDs on bone in postmenopausal Wistar
rats.
Methods: Sixteen postmenopausal Wistar rats were divided into four groups: (i) control
group, (ii) Streptozotocin-induced DM group without treatment, (iii) Streptozotocin-
induced DM group with insulin therapy, and (iv) Streptozotocin-induced DM group
receiving rosiglitazone. Pictures of the obtained samples were taken under computer-
equipped photo-light microscope, and bone tissue ratios were calculated in an area of
1 mm2. In this area, trabecular thicknesses were measured from six randomly selected
regions. In addition, femoral neck regions were determined by measuring the farthest
distance.
Results: Compared to the control group, trabecular thicknesses were decreased in
the uncontrolled DM and rosiglitazone groups. In the rosiglitazone-treated group,
trabecular thickness was decreased compared to the uncontrolled DM group. The
histological examination of the bones showed that uncontrolled DM and rosiglitazone
treatment negatively affected the osteoblast and osteocyte activity. Insulin-treated
group had a similar histologic examination compared to the control group.
Conclusion: Our study showed that DM had unfavorable effects on bones, and
rosiglitazone further exerts this effect. However, the negative effect of DM may be
neutralized with the use of insulin.
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1. Introduction
It is well-known that there is an increase in bone fragility in patients with type-1 diabetes
mellitus (DM) [1, 2]. However, there is no data about type-2DMand bone asmuch as type-
1 DM, and the assumption that obesity frequently accompanying in type-2 DM patients
protects patients against bone fracture was accepted [3, 4]. However, epidemiological
studies have shown that, despite the normal-high bone mineral density (BMD), the risk
of fractures increases in type-2 DM patients. These studies show an increased risk of
fracture in non-vertebral regions, especially hip, proximal humerus, and foot [1, 3, 5, 6].
Thiazolidinedione (TZD) is an oral antidiabetic drug group that increases insulin
sensitivity by activation of peroxisome proliferator-activating receptor gamma (PPARγ).
PPARγ is a group of receptors that have important effects on bone metabolism [7, 8].
In vitro studies have shown that PPARγ agonists increase adipogenesis by reducing
osteoblastogenesis over the PPARγ2 receptor. Gimble et al. showed that expression of
adipocyte-specific genes and adipocyte count increased with the addition of pioglita-
zone and rosiglitazone to the cell medium containing bone marrow stromal cells [7]. It
was found that there were fewer adipocytes and more osteoblasts in the bone marrow
stromal cell cultures containing PPARγ insensitive cells [9, 10]. In studies carried out with
osteoclasts, PPARγ agonists have been shown to reduce osteoclast formation [10, 11].
Similar relationships were found in animal studies. With the use of TZD, increased bone
marrow adipocyte count and proportionally decreased bone formation and increased
bone resorption were detected [12–15].
In literature, studies showing the effects of DM and TZD therapies for blood glu-
cose (BG) regulation on bone have been reported [5, 6, 8, 12, 13]. Postmenopausal
animals were selected for the purpose of this study since the negative effects of
TZDs (rosiglitazone and pioglitazone) on bone are seen more prominently in cases
of estrogen deficiency [15]. This study was aimed at clarifying the relationship between
DM and the drugs used in the treatment for DM with bone fragility through detailed
examinations (examination of histomorphometric parameters with light microscope,
histological evaluation) of the effects of DM, BG regulation with insulin, and TZDs
on the bone. The effect of DM, insulin, and rosiglitazone on bone histomorphometric
parameters in postmenopausal streptozotocin-induced diabetic Wistar rats have not
formerly been investigated in the literature.
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2. Materials and Methods
This study was performed at the Faculty of Medicine Experimental Animals Research
Laboratory of Gazi University.
A total of 16 albino Wistar postmenopausal rats were included in the study. All animals
were kept in polycarbonate cages at 22–24°C, 30–40% humidity, and a 12-hr light/dark
cycle. Standard food and sufficient water were given to all animals.
Rats were randomly divided into four groups, each containing four rats. While the first
group was accepted as the control group, with no intervention made and no treatment
given, the other three groups received a single dose of intraperitoneal injection of 50
mg/kg streptozotocin (Sigma-Aldrich, USA) prepared in citrated solution (pH: 4.5). On
the seventh day after the injection, blood sugars were measured with a glucometer
(Accu-Chek, Roche) from the 1/3 distal tail of the rats. Rats were considered diabetic
upon measurements of serum glucose concentration at 270 mg/dl (15 mmol/l) and
above. Twelve rats with induced diabetes were further divided into three subgroups.
No treatment was given to one of the diabetes-induced groups (group 2). Insulin glargine
(Lantus, Sanofi Aventis) as a single subcutaneous injection of 10 U/kg/day (group 3) and
Rosiglitazone (Avandia, GlaxoSmithKline) at a dose of 20 mcg/gr/day by gavage (group
4) were given to the remaining groups.
BG of the animals were measured twice a day, once in the morning and once in the
evening. At the end of the study, the BG measurements of each group were averaged,
and this was stated as the last BG. Weight follow-up was performed once a week.
Animals were euthanized at the end of the sixth week by taking intracardiac blood under
Xylasine hydrochloride 5 mg/kg anesthesia. The right femurs of the rats were dissected
and placed in a solution containing formaldehyde and delivered to the laboratory where
the investigation would be performed.
After the bone materials were kept in a 10% neutral formalin for 72 hr, they were
transferred to the Decastro Solution and kept in it for 30–45 days by refreshing the
solution every day, at the end of this period the materials were allowed to be decalcified.
Decalcified bone tissues were embedded in paraffin by transmitting light microscope
examination. Sections of 6–7-μm thickness were taken from paraffin blocks and stained
with hematoxylin–eosin (H&E) method. Pictures of the obtained samples were taken
under Leica DM4000 (Germany) computer-equipped photo-light microscope. Using the
Qwin package program of this microscope, bone tissue ratio was calculated in an area
of 1 mm2 randomly selected from each glass. In this area, trabecular thicknesses were
measured from six randomly selected regions and the average trabecular thicknesses
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were calculated. In addition, femoral neck regions were determined by measuring the
farthest distance areas in six areas randomly selected from each glass. Measurements
resulted in micron level.
SPSS 11.0 (IBM, Chicago, IL, USA) was used for statistical evaluation of the data.
Descriptive data was given as median. Kolmogorov–Smirnov test was applied to evalu-
ate whether the data was parametric. The significance of the relationship between two
independent groups was studied using the student’s t-test and the significance in the
data within the group was studied using the paired sample t-test. Pearson’s correlation
test was used to evaluate the relation between study variables. If the p-value obtained
as a result of the tests was <0.05, the test result was considered statistically significant.
3. Results
There was no statistically significant difference between baseline BG and body weight
among all groups included in the study. In the evaluation carried out at the end of the
study, there was no statistically significant difference in BG and body weight compared
to the baseline in the control group. In the other groups, there was a significant increase
in BG compared to the baseline. There was a statistically significant weight loss in group
2. While there was a statistically significant weight gain in group 3, there was weight
loss in group 4, however, it was not statistically significant (Table 1).







End BW (gr) P-value
Group 1 116 117 0.83 259 273 0.07
Group 2 120 494 0.001 256 209 0.02
Group 3 108 184 0.04 262 275 0.04
Group 4 111 373 <0.01 263 241 0.05
BG: blood glucose, BW: body weight
Group 1 is the control group, group 2 is the diabetic group without any therapy, group 3 is the diabetic
group receiving insulin, and group 4 is the diabetic group receiving rosiglitazone.
When the BG levels and body weights of the rats were evaluated at the end of
the study, there was a significant increase in the BG values in all three diabetic groups
compared to the control group. Blood glucose values of groups 3 and 4were significantly
lower than group 2 (p< 0.01). This decrease was more pronounced in group 3 compared
to group 4 and was found to be statistically significant (p < 0.01). When the body weights
were evaluated at the end of the study, it was found to be significantly lower in groups
2 and 4 compared to the control group. There was no significant difference in body
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weight level of group 3 compared to the control group. Body weights of groups 3 and
4 were significantly higher than group 2 (Table 1).
All groups were compared in terms of trabecular thickness, femoral neck thickness,
trabecular area, and percentage of trabecular area (trabecular area/total area) (Table 2).
When the control group and group 2 were compared, a statistically significant decrease
in the average trabecular thickness was found in group 2 (p < 0.001). When the control
group and group 3 were compared, a statistically significant decrease in the average
trabecular thickness was found in group 3 (p = 0.009). When the control group and group
4 were compared, a statistically significant decrease in the average trabecular thickness
in group 4 was found (p < 0.001). In addition, it was observed that the trabecular
thickness of group 4 was lower than that of groups 2 and 3, but statistically significant
difference was observed only between groups 3 and 4. Although the average femoral
neck thickness, trabecular area, and percentage of trabecular area decreased in groups
2, 3, and 4 compared to group 1, this reduction was not statistically significant.
TABLE 2: Histomorphometric parameters among the groups.
Group 1 Group 2 Group 3 Group 4
Mean trabecular
thickness (μm)
416.8 286.7𝑎 327.1𝑏 252.4𝑎,𝑐
Mean femoral neck
thickness (μm)
1500.2 1125.9 1456.8 1304.7
Mean trabecular area
(μm2)
560258 509070 556498 469577
Mean percentage of
trabecular area (%)
56 50.8 55.6 46.8
𝑎P < 0.001 compared to group 1; 𝑏P = 0.009 compared to group 1; 𝑐P = 0.02 compared to group 3
Group 1 is the control group, group 2 is the diabetic group without any therapy, group 3 is the diabetic
group receiving insulin, group 4 is the diabetic group receiving rosiglitazone.
Correlation analysis was applied to show the relationship among study variables
(Table 3). Accordingly, a significant negative correlation was found between BG and
mean trabecular thickness andmean femoral neck thickness values. Although there was
a negative correlation between BG and trabecular area, it was not statistically significant.
There was no correlation between baseline body weight and histomorphometric data.
A significant negative correlation was found between the mean blood glucose level and
the final body weight (p < 0.001).
Bone trabeculaewere observed in their usual structure in the form of irregular wedges
in the femoral head sections of the control group. Bone lamellae were prominent in
trabeculae (Figure 1A). In greater magnification examinations, cubic shapes, which are
the active form of osteoblasts located in one row on the outer surface of the trabecula,
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TABLE 3: Correlation analysis between histomorphometric parameters and blood glucose levels.
Trabecular thickness Femoral neck thickness Trabecular area
r P-value r P-value r P-value
Blood
glucose
–0.761 <0.001 –0.562 0.024 –0.382 0.14
were observed. Bone lamellae within the trabecula were detected with their normal
structure parallel to the long axis of the bone. Among the lamellae, osteocytes located
inside their lacunae, and their canalicular structures, were also distinctively normal
(Figure 1B). The light microscopic examinations of the untreated diabetes group revealed
that the trabeculae were relatively thinned in femoral head sections. In general, bone
trabeculae were monitored in their normal order, while missing areas were detected
in some places. Basophilic areas in the appearance of primary bone (immature bone)
were noted in the trabeculae (Figure 2A). The large-magnification examination revealed
that the osteoblasts were squamous, which are their inactive forms. Bone lamellae
were observed with their normal structure, while localized osteocytes between the
lamellae were determined to be hypertrophic in places (Figure 2B). In light microscopic
examinations of the femoral head sections of the diabetic group treated with insulin, the
density of the trabeculae was similar to that of the control group, but it was distinguished
that they were relatively thin in appearance and showed an irregular course (Figure
3A). In large-magnification examinations, osteoblasts were observed to be active in
places with their cubic shapes, and it was determined that osteocytes exhibited a
structure similar to the control group. Bone lamellae were normal (Figure 3B). In the
light microscopic examinations performed in the diabetic group given rosiglitazone,
trabecular loss areas were observed in the trabecular bone tissue of the femoral head,
but in general, trabeculae were observed in normal appearance. In some trabecular
areas, primary bone tissue areas were observed as basophilic stained (Figure 4A). In
large-magnification examinations, osteoblasts were observed in their inactive squamous
forms, while bone lamellae were found to be normal. Similar to the normal control group,
osteocytes with evident canaliculi were detected in their lacunae (Figure 4B).
4. Discussion
Osteoporosis is a frequent metabolic bone disease that progresses with low bone mass
and deterioration in bone microarchitecture, causing an increased risk of fracture [16].
It has been known for a long time that type-1 DM reduces BMD in bone and increases
the risk of fracture [1, 2]. In type-2 DM, although there is an increase in BMD in general,
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Figure 1: Microscopic view of the femoral neck in the control group. Tr: trabeculae; *Bone marrow tissue
(Hematoxylin–Eozin).
Figure 2: Microscopic view of the femoral neck in the diabetic group without therapy. Tr: trabeculae; *Bone
marrow tissue; ◊Irregular bone trabeculae; Basophilic bone sites. Arrowhead: Osteocyte; Arrow: Osteoblast
(Hematoxylin–Eozin).
an increase in the risk of fracture has been detected [3–6, 17, 18]. In previous animal
studies, a disruption in histomorphometric parameters in bone was detected both in
mice with streptozotocin-induced DM representing type-1 DM and Goto-Kakizaki rats
representing type-2 DM [16, 19, 20].
The mechanisms through how DM causes osteopathy are still being researched.
Direct effects of hyperglycemia, insulin insufficiency, low IGF-1 level, and chronic com-
plications of diabetes are among the possible mechanisms that are considered the most
[21, 22].
In vitro studies have shown that PPARγ agonists increase adipogenesis by reduc-
ing osteoblastogenesis through the PPARγ2 receptors [23]. Increased bone marrow
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Figure 3: Microscopic view of the femoral neck in the diabetic group treated with insulin. Tr: trabeculae;
*Bone marrow tissue; ◊Irregular bone trabeculae. Arrowhead: Osteocyte; Arrow: Osteoblast (Hematoxylin–
Eozin).
Figure 4: Microscopic view of the femoral neck in the diabetic group exposed to rosiglitazone. Tr: trabeculae;
*Bone marrow tissue; ◊Irregular bone trabeculae; Basophilic bone sites. Arrowhead: Osteocyte; Arrow:
Osteoblast (Hematoxylin–Eozin).
adipocyte count with the use of TZDs and decreased bone formation were detected
[12, 13, 15]. Negative effects of TZDs on bone are also known by human studies [24, 25].
TZD has been found to have negative effect on bone in in vitro studies, animal and
human experiments.
The effects of TZDs on bone in older mice have been shown to be more pronounced
compared to youths and adults [16]. In addition, in one study, rosiglitazone did not have
a significant effect on bone in normal rats, whereas adverse effects of the application
of rosiglitazone on the bones were found in oophorectomy-performed rats [17]. Also,
an increase in bone marrow adipogenesis was detected in the group that underwent
DOI 10.18502/sjms.v16i1.8937 Page 63
Sudan Journal of Medical Sciences Derya Köseoğlu et al
oophorectomy without medication, and with this finding, it was thought that estrogen
deficiencymay activate PPARγ [17]. It was thought that the administration of rosiglitazone
to this group, in which PPAR γ activity was increased, had the negative effect on the
bone more pronounced. For these reasons, postmenopausal Wistar rats were used in
our study to see the effects of TZDs more clearly. In addition, both osteoporosis and DM
are more common in the postmenopausal period in humans, and therefore the use of a
treatment agent that has a negative effect on bone becomes more important in patients
in this group. Therefore, rats in the postmenopausal period, which are at higher risk for
osteoporosis, were included in our study. In this study, the effects of diabetes, blood
glucose therapy with insulin, and TZD treatment on bone histomorphometric parameters
were evaluated using postmenopausal Wistar rats. Since both DM and rosiglitazone
have a negative effect on bone, mice were induced diabetes via streptozotocin in order
to reveal the effect of rosiglitazone more clearly. To the best of our knowledge, no
other study has included postmenopausal streptozotocin induced diabetic Wistar rats
to investigate the effect of DM, insulin therapy, and TZD on bone.
The blood glucose levels followed during the study were high in the diabetic group,
as expected. In the insulin group, although the blood sugar was significantly lower
than the diabetic group, it remained above normal and the blood glucose level after
treatment was detected significantly higher than the baseline. Rosiglitazone was used at
a dose of 20 mcg/gr/day, which has previously been shown to provide effective blood
glucose reduction in rats [26]. Also in our study, although the TZD group had lower
blood glucose values than the untreated diabetes group, it was found that the blood
glucose level in this group was significantly higher than the group receiving insulin. No
difference was detected between the initial blood glucose level in the control group
and the blood glucose levels followed during the study.
At the end of the study, the rats in all groups were compared in terms of trabecular
thickness, femoral neck thickness, trabecular area surface, and the ratio of this surface to
the whole area. In the diabetic group, all parameters decreased compared to the control
group, but only the difference in trabecular thickness was statistically significant. The
fact that the data are not significant in other parameters is probably due to the low
number of the rats. Also in our study, there is insulin deficiency due to pancreatic
damage by applying streptozotocin to rats and it fits more to type-1 DM. The significant
reduction in trabecular thickness detected in our study is in line with the BMD-reducing
effect of type-1 DM found in the literature [1, 27, 28].
There was an increase in all histomorphometric parameters in the group we were try-
ing to achieve blood glucose regulation with insulin therapy compared to the untreated
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diabetic group. When insulin group was compared to control group, although the
trabecular thickness was found to be low, no difference was detected between the
trabecular area surfaces. Similarly, decrease in BMD with diabetes and improvement
with insulin were determined in a rat study formerly [19].
When the TZD group was evaluated, a decrease was detected in all parameters com-
pared to the control group. While the decrease in trabecular thickness was statistically
significant, statistical significance could not be achieved despite the significant decrease
in other values. This situation was attributed to the low number of rats in the groups.
In the rosiglitazone-administered group, there was a decrease in trabecular thickness
and rate of trabecular area compared to the untreated diabetes group, therefore the
decrease in this group was interpreted as the effect of TZD with hyperglycemia. In the
correlation analysis, a negative correlation was found between the increased blood
glucose and trabecular thickness. As a result, it is of note that while the average
blood glucose in the TZD group decreased compared to the untreated group, there
was disruption in the bone histomorphometric parameters compared to the untreated
group. The results are in compliance with the literature [8, 12, 13, 29].
In addition to histomorphometric measurements, the femoral sections of the rats
were subjected to histological examination. In this study, bone trabeculae in the control
group were observed in their usual structure. Osteoblasts were detected in their active
cubic forms. When the untreated diabetes group was examined, areas of thinning of
trabeculae and missing areas in trabeculae were found in some places. In addition,
immature bone tissues and squamous cells which are the inactive form of osteoblasts
were detected in this group. In the insulin-administered group, the density of trabec-
ulae was found similar to the control group, but relative thinning was detected in the
trabeculae. In this group, active osteoblasts in similar structure to the control group
were detected. When rosiglitazone-administered group was examined, in general, the
trabecular structure was in natural appearance although some areas of trabeculae were
found to be missing. Immature bone tissue and inactive osteoblasts were observed,
similar to the untreated diabetes group. As a result of histological examination, it was
found that the presence of diabetes and the use of rosiglitazone caused negative effects
on bone continuity by negatively affecting osteoblast and osteocyte activity, and it was
observed that an improvement in bone histology can be achieved with insulin.
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5. Conclusion
In our study, it was observed that in postmenopausal streptozotocin-induced diabetic
Wistar rats, transforming the rats diabetic decreased trabecular thickness and trabec-
ular area rates among bone histomorphometric parameters; improvement of histomor-
phometric parameters can be achieved by treating diabetic postmenopausal Wistar
rats with insulin; histomorphometric parameters worsened with TZD compared to the
untreated diabetes group; similar to the histomorphometric findings, in the histological
examination, the untreated diabetic group and TZD group had decreased osteoblast
activity and the histological findings of the group treated with insulin were similar
to the control group. It is known that bone loss with the use of TZD is especially
higher in postmenopausal rats, for this reason, special care should be taken before
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